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In ThIs Issue
•	 survival After sublobar 
Resection vs. Lobectomy 
for Clinical stage IA Lung 
Cancer: An Analysis from 
the national Cancer Data 
Base
Researchers retrospectively reviewed a total of 13,606 patients with 
T1A N0 NSCLC from the National Cancer Data Base, who were 
treated with lobectomy, segmentectomy, or wedge resection from 
2003 to 2011, and compared their overall survival (OS) and 30-day 
mortality. Median OS for lobectomy, segmentectomy, and wedge 
resection were 100, 74, and 68 months, respectively (p<0.001) 
while no difference was observed in 30-day mortality. Signiﬁcantly 
worse OS was associated with segmentectomy and wedge 
•	 A new Prognostic 
score supporting 
Treatment Allocation for 
Multimodality Therapy 
for Malignant Pleural 
Mesothelioma: A Review 
of 12 Years’ experience
The authors analyzed 186 patients with malignant pleural 
mesothelioma (MPM) of clinical stage T1–3 N0–2 M0, treated 
with induction chemotherapy (cisplatin/gemcitabine [cis/gem] 
or cisplatin/pemetrexed [cis/pem]) followed by extrapleural 
pneumonectomy (EPP) from 1999 to 2011, to determine selection 
factors for patient allocation to multimodal therapy. No difference 
in overall survival (OS) or response was observed between 
In ThIs Issue/ReseARCh WATCh/neWs In BRIef/neWs fRoM The IAsLC  
ToBACCo ConTRoL CoMMITTee
resection versus lobectomy (hazard ratio [HR] 1.70 
and 1.45, respectively; both p < 0.001). Compared with 
lobectomy, segmentectomy and wedge resection were 
associated with higher incidence of positive surgical 
margins (by 2.6%), higher incidence of having 3 or less 
lymph nodes examined (by 55% and 33%, respectively), 
and lower rates of nodal staging (by 5% and 4%, 
respectively). Taken together, the ﬁndings demonstrated 
signiﬁcantly improved OS after lobectomy compared 
with sublobar resection for the study patient population, 
independent of treatment facility type, extent of 
resection, or tumor size. Moreover, sublobar resection 
was more likely to lead to inadequate lymphadenectomy 
and positive margins. Lobectomy should remain the 
standard of care for these patients. Further prospective 
studies are required to take into account lymph node 
upstaging and margin status, and determine the optimal 
surgical procedure for these patients. (p. 1625)
the regimens, with signiﬁcantly lower incidence of 
hematologic toxicity in the cis/pem arm versus the cis/
gem arm. A 30-day mortality of 4.7% was reported 
in 128 patients given EPP. Adjuvant radiotherapy was 
given to about half of the patients. EPP signiﬁcantly 
improved median OS of patients (22 months versus 
11 months without EPP). A multiprognostic score was 
developed and validated by an independent cohort 
based on tumor volume, histology, C-reactive protein 
level, and response to chemotherapy before surgery 
to stratify MPM patients for multimodality treatment. 
In summary, overview of the 12 years’ experience 
with induction chemotherapy (cis/gem and cis/pem) 
followed by EPP for the study patient population 
reported a median OS of about 2 years. While both 
chemotherapy regimens showed no advantage in 
survival and response, cis/pem reduced hematological 
toxicity. The new prognostic score could help MPM 
patient allocation for surgery, and will be further 
improved by integrating with other biomarkers, which 
warrants prospective studies. (p. 1634)
Image credit: Hellerhoff | Wikimedia 
Commons | CC-BY-SA-3.0
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•	 spatiotemporal T790M 
heterogeneity in 
Individual Patients with 
EGFR-Mutant non–small-
Cell Lung Cancer after 
Acquired Resistance to 
eGfR-TKI
in all 22 patients. A spatial heterogeneous T790M 
was uncovered in the thoracic lesions of 3 patients. 
The analysis of 24 patients with repeated rebiopsies at 
the same lesion (lung tissues, cerebrospinal fluid and 
pleural effusions) demonstrated that the thoracic T790M 
status in 5 patients changed from positive to negative 
after TKI-free interval, and 3 of the 5 patients changed 
from T790M-negative to positive again following 
further TKI exposure. One patient changed from CSF-
T790M-negative to positive after high-dose erlotinib 
treatment. Taken together, spatial heterogeneous T790M 
status in an individual patient could be affected by 
selective pressure from EGFR TKI therapies. Further 
investigations are required to better understand 
the relationship between spatiotemporal T790M 
heterogeneity and EGFR TKI therapy. (p. 1553)
•	 Impact of Positive nodal 
Metastases in Patients with 
Thymic Carcinoma and 
Thymic neuroendocrine 
Tumors
Ninety-two patients (40.2%) had at least one lymph 
node with positive metastasis. Higher incidence of 
nodal metastasis was found in patients with thymic 
neuroendocrine tumors versus thymic carcinoma (62.3% 
vs. 33.5%), and was associated with more advanced 
tumors. A signiﬁcant association between nodal 
metastases and worse survival was established (hazard 
ratio, 2.933; p = 0.001), with median survival of  
47 months in patients with positive nodal metastasis 
versus 124 months in those that were negative (p 
< 0.001). All in all, nodal metastases from thymic 
carcinoma and thymic neuroendocrine tumors could be 
an important indicator for poorer prognosis. The authors 
suggested incorporating nodal sampling into surgical 
resection of these diseases, if this ﬁnding is conﬁrmed 
by further prospective studies. (p. 1642)
ReseARCh WATCh
•	 Intraoperative Molecular 
Imaging Can Identify Lung 
Adenocarcinomas During 
Pulmonary Resection
Okusanya et al. investigated the use of a targeted molecular contrast 
agent that could bind to and identify lung adenocarcinomas through 
fluorescence during pulmonary surgery, enabling real-time optical 
imaging. Fifty patients with diagnosed lung adenocarcinoma were 
given 0.1 mg/kg of a fluorescent folate receptor alpha (FRα)–targeted 
molecular contrast agent by intravenous infusion, followed by in 
situ and ex vivo imaging of tumors. This resulted in fluorescence of 
92% of lung adenocarcinomas, ranged from 0.3 to 7.5 cm, including 
2 tumor metastases (3 mm and 6 mm) that were undetected before 
surgery. Of the 50 cases, 14% were fluorescent and detected in situ 
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The retrospective study analyzed the dynamic variation of 
epidermal growth factor receptor (EGFR) mutation T790M status 
and clinical course of 145 patients with EGFR-mutant NSCLC 
who had multiple rebiopsies after acquired resistance to EGFR TKI 
therapy. Of 145 patients, 12 out of 22 patients receiving rebiopsies 
from both central nervous system (CNS) and thoracic lesions had 
T790M in their thoracic lesions while no CNS T790M was found 
The incidence and prognostic signiﬁcance of nodal metastases 
in patients with thymic carcinomas (n=176) and thymic 
neuroendocrine tumors (n=53) were being evaluated based on data 
from the Surveillance, Epidemiology and End Results database. 
Nodal sampling involved a median of 3 lymph nodes per patient. 
by molecular imaging; 78% appeared fluorescent after 
the overlying tissue was opened and the tumor exposed; 
8% without fluorescence were further shown that they did 
not express FRα for the contrast agent to bind to. Tumor 
fluorescence was independent of nodule size, uptake of 
2-deoxy-2-(18F)fluoro-D-glucose, histology, and tumor 
differentiation. Distance of nodule from the pleural 
surface was the most important predictor of successfully 
detecting the tumor in situ. To conclude, this technology 
could safely detect lung adenocarcinomas, irrespective of 
size. Further improvement would allow tumor localization 
deeper in the lung parenchyma, lumph nodes and at 
pleural and resection margins.
Okusanya OT, DeJesus EM, Jiang JX, et al. 
Intraoperative molecular imaging can identify lung 
adenocarcinomas during pulmonary resection. J Thorac 
Cardiovascr Surg 2015;150:28–35.e1.
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•	 Genetic Determinants of 
Telomere Length and Risk 
of Common Cancers: A 
Mendelian Randomization 
study
A large-scale genetic study investigated the relationship between 
telomere length (TL) and risk for 5 common cancers (breast, lung, 
colorectal, ovarian and prostate cancer, including subtypes) using 
genome data from 51, 725 cases and 62, 035 controls via the 
GAME-ON (Genetic Associations and Mechanisms in Oncology) 
network. Researches used Mendelian randomization, which calculates 
telomere length based on genetic factors and allowed unbiased 
comparisons to cancer risk. In the analysis of 9 TL-associated 
SNPs, an inverse-variance weighted average of the SNP-speciﬁc 
associations was used to estimate the relationship between a genetic 
score representing long TL and cancer risk. A signiﬁcant association 
between long TL genetic score and increased risk of 
lung cancer was observed (P = 6.3 × 10−15). The risk 
for lung cancer more than doubled for every 1,000 bp 
increase in TL (odds ratio = 2.78). No other cancer types 
or subtypes were signiﬁcantly associated with TL SNP 
score. There were also no associations between shortened 
telomeres and cancer risk. In summary, the ﬁndings under 
Mendelian randomization assumptions suggest that longer 
TL increases lung cancer risk. Although the estimate 
of a causal relationship could guide future therapeutic 
interventions, the researchers cautioned on potential issue 
of pleiotropy.
Zhang C, Doherty JA, Burgess S, et al. Genetic 
determinants of telomere length and risk of common 
cancers: a Mendelian randomization study. Hum Mol 
Genet July 2, 2015 [Epub ahead of print].
•	 solid Predominant 
histologic subtype in 
Resected stage I Lung 
Adenocarcinoma Is an 
Independent Predictor 
of early, extrathoracic, 
Multisite Recurrence and 
of Poor Postrecurrence 
survival
and P = 0.011, respectively). In patients who recurred, 
poorer PRS was signiﬁcantly associated with solid 
predominant histologic pattern in the primary tumor 
(hazard ratio [HR], 1.76; P = 0.016), ≥ 65 years of age 
(HR, 1.63; P = 0.01), and sublobar resection (HR, 1.6; 
P = 0.01). Worse PRS also signiﬁcantly correlated with 
extrathoracic metastasis (HR, 1.76; P = 0.013) and ≥ 
65 years of age (HR, 1.7; P = 0.014) at diagnosis. The 
analysis demonstrated that solid predominant histologic 
subtype is an independent predictor of early recurrence 
and worse PRS in patients with stage I primary lung 
adenocarcinoma. The ﬁndings support further studies 
into adjuvant therapy and novel targeted therapeutic 
intervention for this patient populations.
Ujiie H, Kadota K, Chaft JE, et al. Solid predominant 
histologic subtype in resected stage I lung adenocarcinoma 
is an independent predictor of early, extrathoracic, 
multisite recurrence and of poor postrecurrence survival.  
J Clin Oncol 2015;33:2877–2884.
The study reviewed 1,120 patients with resected stage I lung 
adenocarcinoma (1999–2009), which were subtyped based on the 
International Association for the Study of Lung Cancer, American 
Thoracic Society, and European Respiratory Society (IASLC/ATS/
ERS) classiﬁcation, in order to examine the effects of the histologic 
subtypes on recurrence, and on postrecurrence survival (PRS) for 
patients who recurred after resection of their tumors. Recurrent 
disease was found in 188 patients, who had a 2-year PRS of 45%, 
and a median PRS of 26.1 months. Recurrences were earlier, more 
extrathoracic, and more multisite in patients with solid predominant 
tumors versus those with nonsolid tumors (P = 0.007, P < 0.001, 
•	 eGfR Independent 
Mechanisms of Acquired 
Resistance to AZD9291 
in eGfR T790M-Positive 
nsCLC Patients
at the metastatic site with different pathways of acquired 
resistance to AZD9291. The ﬁndings indicate co-existence 
of T790M-positive and wild-type T790 clones at baseline 
in cancers with acquired resistance to initial EGFR-TKI. 
The wild-type population grows and develops resistance 
via an EGFR independent pathway (HER2 or MET 
activation) as AZD9291 blocks the growth of T790M-
positive population. The observation warrants further 
investigations, which, if conﬁrms, could lead to rationale 
targeting HER2 or MET pathways in these patients.
Planchard D, Loriot Y, Andre F, et al. EGFR 
independent mechanisms of acquired resistance to 
AZD9291 in EGFR T790M-positive NSCLC patients. 
Ann Oncol August 12, 2015 [Epub ahead of print].
This report described the potential mechanisms of resistance to 
AZD9291, an EGFR-TKI that targets both sensitizing and resistant 
T790M mutations, in 2 EGFR T790M-positive NSCLC patients who 
were treated with AZD9291. Using FISH And CGH, HER2 and MET 
ampliﬁcation were identiﬁed as a potential mechanism of acquired 
resistance to third-generation EGFR-TKI, interestingly in the absence 
of T790M mutation. Different molecular statuses at 2 biopsy sites were 
observed: T790M mutation at the primary site and wild-type T790M 
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•	 secondhand smoke and 
Atrial fibrillation: Data 
from the health eheart 
study
AF and having had a smoking parent during  
gestational development (odds ratio [OR] 1.37;  
P =0.009), and residing with a smoker during 
childhood (OR 1.40; P=0.007). Patients with no risk 
factors for AF demonstrated stronger of both positive 
associations (P values for interaction <0.05). In 
summary, the data implicated the role of SHS exposure 
early in life, which could be targeted in the intervention 
of AF development.
Dixit S, Pletcher MJ, Vittinghoff E, et al. 
Secondhand smoke and atrial ﬁbrillation: Data from the 
Health eHeart Study. Heart Rhythm August 25, 2015 
[Epub ahead of print].
•	 Increased Lung Cancer 
Mortality Rates in the 
Chinese Population from 
1973–1975 to 2004–2005: 
An Adverse health effect 
from exposure to smoking
and 1973–1975 (53.65 per 100,000). Of the 6674 
lung cancer patients from the hospital-based database, 
ever-smokers accounted for 82.97% of men (73.35% 
adenocarcinoma, 91.8% squamous cell carcinoma), 
and 11.18% of women (6% adenosquamous carcinoma, 
39.02% squamous cell carcinoma). Taken together, the 
ﬁndings demonstrated consistent and dramatic increases 
in lung cancer mortality rates in the Chinese population, 
and high incidence of smoking exposure, implicating 
the need for enhanced tobacco-control policy and public 
health approaches.
Zhi XY, Zou XN, Hu M, et al. Increased lung 
cancer mortality rates in the Chinese population 
from 1973–1975 to 2004–2005: An adverse 
health effect from exposure to smoking. Cancer 
2015;121:3107–3112.
neWs In BRIef
•	 fDA Grants orphan 
Drug Designation to 
MTG-201 for Malignant 
Mesothelioma
leads to the absence of REIC (Reduced Expression 
in Immortalized Cells) protein. By expressing REIC 
protein from within cancer cells, MTG-201 selectively 
induces apoptosis and kills the cancer cells. It also 
induces cancer speciﬁc activation of T-cell lymphocytes 
that target residual cancer and secondary tumors. 
Mesothelioma has been demonstrated to be the most 
sensitive cancer to this mechanism of action, and 
therefore MTG-201 is being moved into phase I trial 
for this disease. MTG-201 could also be combined with 
checkpoint inhibitors such as anti-CTLA-4 with high 
synergistic effects for mesothelioma.
The study investigated the impacts of secondhand smoke (SHS) 
on the risk of atrial ﬁbrillation (AF) through a cross-sectional 
analysis of data from the Health eHeart Study in which participants 
completed online questionnaires on baseline SHS exposure and 
medical conditions. AF was being reported in 11.9% of participants 
(593 of 4976). Unadjusted analyses showed an association between 
AF and SHS exposure in utero, as a child, as an adult, at home, and 
at work. Multivariate adjustment showed signiﬁcant links between 
This study evaluated 3 National Death Surveys and a hospital-based 
information system (1973 to 1975, 1990 to 1992, and 2004 to 2005) 
to estimate age-standardized mortality rates and age-speciﬁc rates 
of lung cancer in China, and the incidence of ever-smokers based 
on histologic and demographic variables. Substantial increase in 
lung cancer age-standardized mortality was observed from 7.30 per 
100,000 (1973-1075) to 27.62 per 100,000 (2004–2005), consistent 
among men and women in urban and rural areas. Men aged 75–79 
years had dramatically higher lung cancer mortality in 2004 and 
2005 (453.67 per 100,000) than in 1990–1992 (246.78 per 100,000) 
Image source: FDA
MTG-201, which targets Dickkopf-3 gene defects in cancers, 
received Orphan Drug Designation from the FDA for the treatment 
of patients with malignant mesothelioma. Cancer cells are 
immortalized by hypermethylation of the Dickkopf-3 gene that 
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•	 fDA Grants nivolumab 
Priority Review in 
nonsquamous nsCLC
Nivolumab has received priority review designation 
from the FDA for the treatment of patients with 
advanced nonsquamous non-small cell lung cancer 
(NSCLC) who failed on platinum-based doublet 
chemotherapy. A breakthrough therapy designation 
has also been simultaneously granted to nivolumab by 
the FDA in this setting. The designations are based on 
ﬁndings from the phase III CheckMate-057 study that 
demonstrated second-line nivolumab cut the risk of 
death in patients with nonsquamous NSCLC by 27% 
versus docetaxel, particularly a 60% risk reduction 
in those with the highest levels of PD-L1 expression. 
Nivolumab was approved in March 2015 for treating 
patients with squamous cell NSCLC who progressed on 
or after platinum-based chemotherapy.
Image source: NCI
•	 WCLC 2015: A 
Randomized, Phase 
III study Comparing 
Carboplatin/Paclitaxel or 
Carboplatin/Paclitaxel/
Bevacizumab with or with-
out Concurrent Cetuximab 
in Patients with Advanced 
non-small Cell Lung 
Cancer (nsCLC): sWoG 
s0819 (PLen04.01)
co-primary objectives. OS in FISH+ patients, 
and clinical outcomes between the bevacizumab-
appropriate and inappropriate patients were secondary 
objectives. FISH + patients accounted for 41% 
(400/976) while squamous carcinoma (SCCA) 
accounted for 24–25% of patients. No statistically 
signiﬁcant difference of PFS and OS was observed 
in the OSP (hazard ratio [HR] = 0.98 and 0.94, 
respectively) and FISH+ patients (HR = 0.91 and 0.83, 
respectively). The ﬁndings however suggest beneﬁt in 
FISH+ BI and SCCA patients (OS estimates: 0.75 and 
0.56, respectively). The addition was well-tolerated 
and no new adverse events were reported. In summary, 
cetuximab did not improve clinical outcomes of the 
study population when added to carboplatin/paclitaxel 
or carboplatin/placlitaxel/bevacizumab in unselected 
patients. The ﬁndings warrant further evaluation of 
new markers to identify patients likely to beneﬁt from 
chemotherapy in combination with cetuximab.
•	 WCLC 2015: Randomized 
Phase III Trial of Adjuvant 
Chemotherapy with or 
without Bevacizumab in 
Resected non-small Cell 
Lung Cancer (nsCLC): 
Results of e1505 
(PLen04.03)
histology 28.2%. At a median follow-up of 41 months, 
there was no signiﬁcant difference in overall survival 
(OS) between chemotherapy alone and in combination 
with bevacizumab (hazard ratio [HR] = 0.99; p=0.93), 
and in disease-free survival (DFS) (HR = 0.98; p=0.75). 
There was signiﬁcant increase in grade 3–5 toxicities 
with bevacizumab addition, including overall worst 
grade (67% vs. 84%), hypertension (8% vs. 30%), and 
neutropenia (33% vs. 38%). Bevacizumab addition 
did not increase grade 5 adverse events. All in all, 
bevacizumab addition to adjuvant chemotherapy did not 
improve survival for patients with surgically resected 
early stage NSCLC.
Roy Herbst presented one of the top 4 abstracts at the Presidential 
Symposium, on data of the open-label, multicenter, phase III 
trial assessing the addition of cetuximab to carboplatin/paclitaxel 
or carboplatin/placlitaxel/bevacizumab in 1, 313 patients with 
newly diagnosed or recurrent Stage IV NSCLC. Patients were 
randomized according to appropriateness for bevacizumab 
treatment, smoking status, and M-substage. Progression-free 
survival (PFS) in EGFR-FISH positive (FISH+) patients and 
overall survival (OS) in the overall study population were 
At the Presidential Symposium, Heather Wakelee reported the 
ﬁndings of a decade of work from the phase III study on the effect 
of adding bevacizumab to adjuvant chemotherapy in 1501 patients 
with resected stage IB to IIIA NSCLC. Stage IB tumors accounted 
for 26.2%, stage II 43.8%, stage IIIA 30.0% and squamous cell 
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•	 WCLC 2015: Multiregion 
Whole exome and 
Transcriptome sequencing 
Defines the Genomic 
spectrum of eGfR+ 
nsCLC and Reveals 
novel Mechanisms of TKI 
Resistance (PLen04.05)
Another Presidential Symposium Top Abstract was presented by 
Daniel S-W Tan, on using multiregion whole exome and transcriptome 
sequencing to determine the genomic structure and spectra of 
EGFR mutant (M+) NSCLC, leading to enhanced understanding of 
underlying mechanisms of treatment failure. Analyses were performed 
on 30 tumor biopsies from 25 patients with TKI resistance (TKI-R), 
and 46 regions of 8 resected EGFR M+ NSCLC from TKI naïve 
(TKI-N) East Asian never smokers (Stage IA and IB). A median 
of 52.5 validated mutations per tumor were found in the TKI-N 
samples; primary EGFR mutations were truncal events in all cases, 
while T790M was absent in ultra-deep sequencing, and 
private mutations contributed to 10–33% of all mutations 
per tumor. TKI-R tumors (T790M+ and T790M-) had 
higher mutation burden versus TKI-N (median 80 vs. 
49), and had ERBB2 and MET as common co-existing 
resistance mechanisms. TKI-N tumors had 39 of 112 
mutations that were truncal events, where MAP3K19 and 
PTEN mutations co-existed with EGFR L858R mutation. 
Comparison of transcriptomic proﬁles of TKI-N and 
TKI-R indicated implications of truncal co-mutations 
in primary TKI resistance. Approximately 150 recurrent 
genes or putative drivers, 85% of which were trunk or 
branch mutations, were identiﬁed. Taken together, this 
study demonstrated low mutation burden and signiﬁcant 
truncal or branch alterations in the TKI-N tumors. 
Activating EGFR mutations were ubiquitously truncal 
mutations, with the absence of T790M. TKI treatment 
failure was associated with co-existing truncal events.
•	 WCLC 2015: stopping 
smoking Reduces 
Mortality in Low-Dose 
Computed Tomography 
(LDCT) screening 
Volunteers (PLen04.07)
The study, presented by Ugo Pastorin at the Presidential Symposium, 
was designed to assess the impact of smoking habits on the overall 
mortality of individuals receiving LDCT screening. Heavy smokers 
(n=3381), of 69% males, aged median 58 years, with 40 pack-years, 
were enrolled in 2 LDCT screening programs and divided into 
current smokers throughout screening, and former smokers (early 
quitters who quitted at time of baseline screening, and late quitters 
who quitted during screening). After a median follow-up 
of 9.7 years and a total of 32, 857 person/years (P/Y) 
follow-up, deaths were observed in 151 of 1797 current 
smokers and in 109 of 1584 former smokers. The relative 
risk (RR) of death of former smokers versus current 
smokers was 0.77 (p=0.0416), a 23% reduction of total 
mortality. The RR was 0.64 (p=0.016) when excluding 
239 individuals who quitted for < 2 years from the end-
point of follow-up, with a 36% mortality reduction. Late 
quitters (n=476) also showed a similar risk reduction 
(RR = 0.60; p=0.0158). In summary, smoking cessation 
is correlated with a signiﬁcant reduction of overall 
mortality of heavy smokers involved in LDCT screening 
programs, with a 3 to 5-fold greater beneﬁt compared to 
that as a result of early detection in the NLST trial.
•	 WCLC 2015: safety and 
efficacy of first-Line 
nivolumab (nIVo; Anti-
Programmed Death-1 
[PD-1]) and Ipilimumab 
in non-small Cell 
Lung Cancer (nsCLC) 
(oRAL02.05)
NIVO has been approved in the US for treating metastatic squamous 
(SQ) NSCLC patients whose disease progressed on or after platinum-
based chemotherapy. This study assessed the efﬁcacy and safety of 
ﬁrst-line NIVO in combination with the ipilimumab (IPI), an IgG1 
CTLA‐4 checkpoint receptor blocking antibody, in chemotherapy-naïve 
patients with stage IIIB/IV NSCLC. Patients (n=148) received NIVO and 
IPI in combination at either 1+3 mg/kg or 3+1 mg/kg, in squamous and 
non-squamous cohorts. Clinical activity was observed across histologies 
in all dosing regimens, independent of tumor PD-L1 
expression. Objective response rate (ORR; RECIST v1.1) 
was 13% to 39%, and median progression-free survival 
time was 4.9 to 10.6 months. Only partial responses were 
observed, with a higher rate in the 3+1 mg/kg arm versus that 
in the 1+3 mg/kg arm. Unconventional “immune-related” 
response was achieved in 2 patients in the 3+1 mg/kg arm, 
with 56% and 64% maximum reductions in target lesions 
and development of new ones. Treatment-related grade 3/4 
adverse events were skin reactions (3% to 13%), endocrine 
(3% to 8%), gastrointestinal (< 9%), and pneumonitis (0% 
to 3%), resulting in < 10% discontinuation. The phase I data 
suggest durable responses and survival with the combination 
of NIVO and IPI, independent of PD-L1 levels, with a 
manageable safety proﬁle.
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neWs fRoM The 
IAsLC ToBACCo 
ConTRoL 
CoMMITTee
This column was written during the inspiring 
pandemonium of the 2015 World Conference in Lung 
Cancer, in Denver. Tobacco control had a strong presence 
at the meeting with discussions and sessions covering 
everything from survival in lung cancer to federal 
regulation of tobacco products. So, where to start.
•	 TPPA update
Obama said, it’s “the big bugaboo” and what he is talking about 
is the tobacco control shadow hanging over the Trans Paciﬁc 
Partnership Agreement, currently being developed between a 
number of Paciﬁc Rim countries, including the USA, Mexico, 
Canada and Australia, a group that covers a large proportion of the 
world economy. This is how Obama described the uncertain fate of 
tobacco control, in a report on politico.com1, and it is an apt term 
to use when describing the uncertain fate of tobacco control in the 
murky negotiations of the Trans Paciﬁc Partnership Agreement.
“The big bugaboo that’s lifted up there is tobacco companies 
suing poorer countries to make sure that anti-smoking legislation 
is banned, or at least tying them up with so much litigation that 
ultimately smaller countries cave”
This report, entitled “Will Trans-Paciﬁc trade deal go up in 
smoke over anti-tobacco proposal?”, discusses the ins and outs 
of negotiating the TPPA around the concerns of both 
the pro- and anti-tobacco lobbies. As we know from 
previous columns, Big Bully (PMI, BAT, JTI etc) are 
more than happy to use Inter-State Dispute Settlement 
(ISDS) provisions included in trade treaties to upset the 
internal policies of other countries. That’s how PMI cost 
Australia $50 million (and counting) in their opposition 
to plain packaging (which seems to be working a treat on 
smoking rates there). As far as current US negotiations 
go says the report, the powerful Senate Majority Leader 
Mitch McConnell, initially an Obama supporter in 
the negotiations, has warned against setting a “new 
precedent for future U.S. trade negotiations by negatively 
carving out a speciﬁc American agricultural commodity 
— in this case tobacco.”. When PMI attacked Australia’s 
plain packaging legislation, it didn’t use the TPPA (it’s 
not signed yet, they used another treaty) but the ISDS 
provisions potentially included in the TPPA could give 
rise to another Big Bully free-for-all around the Paciﬁc.
•	 Taking on Dutch Corner A recent new report in the BMJ is worth a look2. 
Briefly, two Dutch pulmonologists are taking the Dutch 
government to court, arguing that the government is in 
breach of its FCTC obligations because of excessive 
interaction with and influence of the tobacco industry. 
There are concerns about casual, informal and excessive 
communications between government ofﬁcials and 
lobbyists. A hearing is due in September.
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•	 Tobacco Advertising 
Restrictions in China
A report from the WHO welcomes new tobacco 
advertising restrictions in China3. As of 1 September, 
new restrictions will be put into place. Before this, 
advertising was permitted on billboards and some public 
places. After this, tobacco advertising will be banned 
in all mass media, in public places, on public transport 
and outdoors. The China Daily carried the same report4 
with a pertinent link at the bottom of the web page to an 
article entitled “Beijingers enjoy blue skies for 15 days”.
•	 CVs Pharmacy Tobacco 
free update
And lastly, pharmacy power. Readers may remember 
from previous columns that some time ago the CVS 
pharmacy chain in the US removed tobacco products 
from its shelves. A year on, they have released data 
that shows (from external data sources) an decrease in 
tobacco sales and an increase in nicotine patch sales in 
states where CVS has a large presence. Well done.
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